Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06493019 · ClinicalTrials.gov registry record · Phase 2

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

A Phase 2 study of Anal Cancer, sponsored by Dustin Deming.

Recruiting
Registry status
Phase 2
Development phase
23
Enrollment target
4
Study locations

NCT06493019 is a Phase 2 study of Anal Cancer that is actively recruiting participants, run by Dustin Deming. The registered enrollment target is 23 participants, below the 579-participant average among 19 other Anal Cancer trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06493019, a Phase 2 study of Anal Cancer, is actively recruiting participants, sponsored by Dustin Deming.

RECRUITING
Registry status
Phase 2
Development phase
23 participants
Enrollment target
4
Study locations

Study Summary

A single arm phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer. There are 2 treatments phases and then surveillance. The first treatment phase is the chemoradiation phase (Cycle 1-6, weekly cycles) which is followed by the maintenance phase (Cycle 7-14, 6 week cycles).

Conditions Studied

Anal Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Paclitaxel
  • RADIATION Radiation

Study Locations (4)

Indiana

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis

Maryland

  • University of Maryland - Baltimore

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2024-09-30
Est. Completion 2029-04-14
Phase Phase 2

Sponsor

Dustin Deming

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06493019

The ClinicalTrials.gov registry entry for NCT06493019 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 579-participant average among 19 other Anal Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Dustin Deming, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT06493019 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Indiana, Maryland, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06493019 about?

NCT06493019 is a clinical study titled "Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer". A single arm phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer. There are 2 treatments phases and then surveillance. The first treatment phase is the chemoradiation phase (Cycle 1-6, weekly cycles) which is followed by the maintenanc...

What is the current status of trial NCT06493019?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2024-09-30. Estimated completion is 2029-04-14.

What conditions does trial NCT06493019 study?

This clinical trial studies the following conditions: Anal Cancer.

What interventions are being tested in trial NCT06493019?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), Radiation (RADIATION).

Who is sponsoring clinical trial NCT06493019?

This trial is sponsored by Dustin Deming, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06493019 being conducted?

This trial has 4 study locations across Indiana, Maryland, New Jersey, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anal Cancer

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.